Q-omics provides the consensus-scored PSG1 profile across patient tissues and cancer cell-line models. PSG1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PSG1 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, PSG1 RNA expression shows 9,094 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, THCA, and GBM as cancer lineages where PSG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSG1 survival associations across molecular data types. PSG1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSG1 RNA expression–survival associations across cancer types. High PSG1 expression shows unfavorable associations in MESO, KIRC, COAD, DLBC and SCLC, but favorable associations in THCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PSG1 RNA expression.
This table summarizes PSG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PSG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSG1 shows lower tumor expression in PAAD and higher tumor expression in THCA, HNSC, KIRC, LUAD and KIRP. The THCA box plot shows higher PSG1 RNA expression in tumor versus normal tissue (log2 FC = +0.871, t-test p < 0.001).
This table shows molecular features associated with PSG1 in patient tissues and cancer cell lines. In patient samples, PSG1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PSG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
